However, the increased tumor immunogenicity along with the reduced IFN-I signature in the tumor of Prdm1fl/flFoxp3YFP-Cre mice, which can potentially sensitize tumors to checkpoint blockade and to potentially destabilize Treg cells [40, 71], justifies a better therapeutic outcome by combining Treg-specific deletion of Blimp1 with anti-PD-1 treatment, as proved in this study. This evidence concerns the gene PDCD1 and neoplasm.